🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

APYX APYX

Company Profile ↓
$4.14
+123.78% 1Y
P/E-7.67
52W High$4.86
52W Low$1.85
EPS (TTM)$-0.54

Company Overview

APYX (APYX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Dec 2025 Revenue of $52.84M (+9.9% YoY); net profit $-11.21M.
  • Trailing 12 Months Year-on-year growth — revenue +9.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.30%
1 Year:9.86%

Stock Price Performance

1 Year:+123.78%
6 Months:-5.69%
3 Months:+48.39%
1 Month:-1.43%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 76% of range
$1.85 $4.86
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)49.96 · Neutral
Price Performance
1M-1.43%
3M+48.39%
6M-5.69%
1Y+123.78%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-7.67
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
4.30%
Profit 5Y
-
Revenue (YoY)
9.86%
Earnings (YoY)
-

Profitability & Returns

ROCE
-11.69%
ROE
-77.10%
ROA
-16.77%
Profit Margin
-21.22%
Op Margin
-12.20%
Gross Margin
62.53%
EPS (Latest Qtr)
$-0.19
EPS (TTM)
$-0.54

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$63.02M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
13.61%
Chg in Prom Hold
-
FII / Inst Holding
51.19%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$52.84M
EBITDA
-
Free Cash Flow
$-9.12M
Operating Cash Flow
$-8.00M
Shares Outstanding
-
Gross Margin
62.53%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------3.40M3.69M3.67M5.84M5.63M6.65M7.58M8.38M5.00M4.30M6.95M8.64M11.22M11.83M12.49M10.29M9.11M12.14M13.57M11.98M10.24M12.15M11.49M9.43M11.37M12.88M12.49M
Gross Profit 2.44M2.67M3.14M3.23M3.51M3.32M4.70M5.06M4.83M777.00K1.57M1.91M2.70M2.21M2.54M2.52M3.56M3.56M4.67M5.29M5.56M2.98M2.09M4.72M5.86M7.53M8.06M8.22M6.91M5.76M7.57M9.28M7.98M5.95M7.49M6.95M5.67M7.08M8.30M7.92M
Operating Income --2.27M-1.55M-1.81M--1.99M-510.00K-245.00K--1.74M-1.31M-2.83M--2.72M-2.93M-2.79M--5.73M-4.42M-4.76M--7.49M-6.17M-4.37M-4.75M-4.04M-3.97M-5.87M-5.98M-5.78M-5.61M-1.24M-4.64M-6.62M-5.55M-3.63M-3.05M-2.57M-832.00K-911.00K
Net Income -5.45M-876.00K-1.50M-1.59M-1.41M-1.94M-519.00K-965.00K--1.69M-1.31M-2.94M--2.79M-2.94M68.47M--4.68M-4.34M-4.37M--1.95M-4.69M-3.73M-4.90M-4.05M-4.22M-5.95M-5.43M-5.76M-3.48M-994.00K-4.63M-7.58M-6.56M-4.70M-4.15M-3.78M-1.98M-2.11M
Diluted EPS -0.310.57-0.06-0.06-0.05-0.07-0.02-0.04--0.06-0.04-0.04--0.03-10.001.96--0.14-0.13-0.13---0.14-0.11-0.14-0.12-0.12-0.17-0.16-0.17-0.10-0.03-0.13-0.22-0.19-----
R&D Expense -446.00K505.00K583.00K-668.00K592.00K681.00K-709.00K696.00K487.00K-514.00K763.00K613.00K-730.00K888.00K1.02M-980.00K975.00K1.05M1.11M1.08M1.18M1.16M1.07M1.06M1.27M1.36M1.41M1.40M1.42M1.14M804.00K824.00K801.00K765.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 26.95M24.23M25.41M27.67M23.66M27.68M29.52M8.82M10.23M16.61M28.23M27.71M48.52M44.51M52.35M48.10M52.84M
Gross Profit 11.86M9.99M10.73M11.33M9.20M8.99M12.56M5.12M6.96M10.83M19.09M17.50M33.60M29.13M33.76M29.36M33.04M
Operating Income 715.00K-2.75M-18.00K1.05M-3.67M-5.85M-6.99M-11.39M-13.88M-14.28M-20.87M-20.08M-14.45M-23.56M-17.26M-18.84M-6.45M
Net Income 596.00K-1.53M109.00K617.00K-4.34M-17.28M-5.37M-11.55M-5.06M62.72M-19.71M-11.90M-15.17M-23.18M-18.71M-23.46M-11.21M
Diluted EPS 0.03-0.090.010.03-0.40-1.030.24-0.15-0.171.83-0.58-0.35-0.44-0.67-0.54--
R&D Expense 2.08M1.85M1.20M1.33M1.26M1.42M2.16M1.03M1.94M2.55M3.73M3.92M4.32M4.54M5.44M5.08M3.37M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Sep 2018Dec 2018Mar 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --27.79M28.24M28.18M33.18M24.83M31.45M35.11M30.99M113.17M95.93M91.86M84.75M74.11M68.72M51.77M79.24M64.84M66.84M
Total Equity 20.22M21.03M21.77M22.12M22.89M19.07M1.50M23.40M26.22M22.03M90.60M87.18M82.83M71.26M63.72M53.70M37.58M26.70M14.21M14.54M
Cash & Equivalents 2.56M2.15M3.83M4.88M4.16M7.92M5.73M11.80M14.46M9.95M40.66M16.60M32.41M58.81M41.91M30.87M10.19M43.65M31.74M31.74M
Long Term Debt -----3.19M-2.93M2.69M2.46M-0----033.19M33.89M34.85M
Total Liabilities --6.02M6.12M5.29M11.85M20.14M8.04M8.89M8.96M22.58M8.75M9.03M13.49M10.25M14.71M13.98M52.32M50.51M52.01M
Current Liabilities --1.80M2.39M1.92M2.91M3.77M4.12M5.27M5.97M22.44M8.61M8.62M12.31M9.15M13.21M11.85M12.74M10.72M11.70M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -97.00K-526.00K1.90M165.00K-2.54M-417.00K-5.79M-2.84M-3.70M-20.88M-18.48M-16.07M-10.45M-20.28M-5.25M-18.05M-8.00M
Investing Cash Flow -2.46M432.00K-542.00K-753.00K-588.00K-630.00K-921.00K-286.00K-624.00K29.30M60.54M-581.00K-723.00K-1.01M6.73M-722.00K-1.11M
Financing Cash Flow 2.15M1.68M-302.00K-130.00K6.89M-1.14M12.78M5.71M-239.00K-2.49M147.00K-73.00K24.00K217.00K32.17M6.75M9.58M
Capital Expenditure -2.46M-201.00K-542.00K-753.00K-588.00K-630.00K-421.00K-286.00K-624.00K-363.00K-1.30M-581.00K-723.00K-1.01M-533.00K-722.00K-1.11M
Free Cash Flow -2.56M-727.00K1.35M-588.00K-3.12M-1.05M-6.21M-3.12M-4.33M-21.24M-19.78M-16.65M-11.17M-21.29M-5.78M-18.77M-9.12M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 44.0%41.2%42.2%41.0%38.9%32.5%42.5%58.0%68.0%65.2%67.6%63.2%69.3%65.4%64.5%61.0%62.5%
Operating Margin % 2.7%-11.4%-0.1%3.8%-15.5%-21.1%-23.7%-129.2%-135.7%-86.0%-73.9%-72.5%-29.8%-52.9%-33.0%-39.2%-12.2%
Net Margin % 2.2%-6.3%0.4%2.2%-18.3%-62.4%-18.2%-131.0%-49.5%377.7%-69.8%-42.9%-31.3%-52.1%-35.7%-48.8%-21.2%
ROE % 2.8%-7.1%0.5%2.7%-22.8%-1,149.1%-22.9%-44.0%-23.0%71.9%-27.7%-18.7%-28.3%-61.7%-70.1%-165.1%-77.1%
ROCE % --10.6%-0.1%4.0%-12.1%-27.8%-25.6%-38.2%-55.5%-16.3%-28.8%-30.9%-26.0%-59.0%-26.0%-34.8%-11.7%

Shareholding Pattern

Insiders
13.61%
Institutions
51.19%
Public Float
59.26%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for APYX

Google News ue, 28 Jul 2026

Apyx Medical CEO and CFO to Hold Aug. 11 Investor Fireside Chat - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOb2ZnbzFoYnlhRFRVVnVqMGJ3d3lLeHlnVUJvQl85M2R3RHZUZU1mYUdTVkZkT21zUldRZml0VDFBaE5Icmlkck51bWFGOHVSZ2pQNGRLSGE2WnNKOXB3YWFSZkx5dlJiZ3diZXZOdFpYQ2tRdllXYXVMMWtSUXMtZHdxaklhbFQ5RENxND…

Google News Mon, 23 Mar 2026

How The Apyx Medical (APYX) Story Is Evolving With New Growth Drivers And Profitability Goals - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNNktaUkhSTFVkRTNtUWpiRG90LXktSzhWR3ZxbDYxakhGZDJpVjBLak1CX3kxMjNPczduZ1lDOFVSdnNNdXlmbUJLLVQwZUdnZS1NcUpra3FYUjRNa3hsN00xak5GTTJ3QVFIUEEtd2F2U2Y4ak82dDY0eFN6N1BGUmlfMjVYT1FkOHZuSm…

Google News Sat, 01 Aug 2026

Earnings Preview: Apyx Medical to Report Financial Results Post-market on August 06 - Moomoo

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOeVA0WUdpQVBzWXc1ZXRGQmVhSDFGclM3S2lCbzZSdFlZdHhsSWo2cWhEUEkwUW1oS2RUUmJBR2NWNjE3ZW0wTUFhdFlkSk0ya19SaGFZSUZ4azJzanRqZ0ljWjB2WXpLOWhZTWxlc1U3T24xUDUwajBDVXhIc1ZKOC1WeG5RdlJFdm1hNl…

Google News Fri, 26 Jun 2026

APYX Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9sZ2cwakt6YWJpVmJwTkNZSklIR19PVktYcEkzZnhoTmRmVnNSd3ZzV09qdFVUUDhnTlBLcVlZZkE2UHVvTHpta2Q3VWZ6Y3hXMldpelJlWTAweTZWVVV6czRaVk5aMV9Obk5DSW9BOW14OFN5NDFoQkhB?oc=5" target="_blank">APY…

Google News ue, 26 May 2026

APYX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1GSFdrLTlKb01aU3JKMGR0UUFubzUyRGF3Sm9lV0VHSUZoXzc3amxFZzQ3S0FoQnBGQ3dyTTgtdExvOGt3MGc?oc=5" target="_blank">APYX</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Fri, 31 Jul 2026

APYX|Apyx Medical Corp|Price:4.179|Chg%:+0.079 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5OeHVINVhub3VyZ2xKRk9xUVNBWnowaFNGVGI0Yl9aVGdtUHJoU1F0MDkxdjNGS1JPcy16ck9XMHFCQlEyMGxYRk9xUkdCcTNtMWFydzBBXzV5LTNlVlY1UDVpdmlQVTRzOUFWdnVn?oc=5" target="_blank">APYX|Apyx Medical C…

APYX — Frequently Asked Questions

What is the current share price of APYX?

As of 2026-08-05 17:25 PDT, APYX trades at $4.14 on NASDAQ/NYSE. Its 52-week range is $1.85 to $4.86.

What is the P/E ratio of APYX?

APYX trades at a trailing price-to-earnings (P/E) ratio of -7.67.

What is the return on equity (ROE) of APYX?

APYX has a return on equity (ROE) of -77.10%. Its return on capital employed (ROCE) is -11.69%.

Is APYX a good stock to buy?

This page provides a data-driven analysis of APYX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space